Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College, PR China.
Curr Drug Targets. 2010 Jan;11(1):29-36. doi: 10.2174/138945010790031027.
The incidence of lung cancer in 2007 is estimated to be 213,380 with 160,390 deaths in the United States. It will contribute to 31% of male and 26% of female cancer-related deaths and is the largest cause of cancer-related mortality in both men and women. Despite some advances in the treatment of advanced non-small cell lung cancer (NSCLC), the introduction of third-generation cytotoxic agents (vinorelbine, gemcitabine, docetaxel, irinotecan, and paclitaxel) has not achieved a breakthrough in the dismal prognosis of this disease. Several meta-analyses have proved the superiority of 2-drug chemotherapy and cisplatin-based chemotherapy, but no gold standard exists. This paper summarizes the clinical data of a new cytotoxic agent, pemetrexed, and its combination with platinums in the treatment of NSCLC. The addition of the vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) or an EGFR-targeted drug (cetuximab) to pemetrexed/platinum in NSCLC, and the role of pemetrexed/platinum in adjuvant chemotherapy for early-stage NSCLC were also discussed in this paper.
2007 年美国肺癌发病率估计为 213380 例，死亡 160390 例。肺癌将导致 31%的男性和 26%的女性癌症相关死亡，是男性和女性癌症相关死亡的最大原因。尽管晚期非小细胞肺癌（NSCLC）的治疗取得了一些进展，但第三代细胞毒性药物（长春瑞滨、吉西他滨、多西他赛、伊立替康和紫杉醇）的引入并没有改善该疾病的预后。几项荟萃分析证明了 2 种药物化疗和含顺铂化疗的优势，但尚无金标准。本文总结了新型细胞毒性药物培美曲塞及其与铂类药物联合治疗 NSCLC 的临床数据。还讨论了在 NSCLC 中将血管内皮生长因子（VEGF）抑制剂（贝伐单抗）或 EGFR 靶向药物（西妥昔单抗）与培美曲塞/铂类药物联合使用，以及培美曲塞/铂类药物在早期 NSCLC 辅助化疗中的作用。
